Comparative Pharmacology
Head-to-head clinical analysis: FOLVITE versus THIAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLVITE versus THIAMINE HYDROCHLORIDE.
FOLVITE vs THIAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folate is reduced to tetrahydrofolate (THF) which acts as a cofactor for single-carbon transfer reactions in nucleic acid and amino acid synthesis.
Thiamine hydrochloride is a water-soluble vitamin that acts as a cofactor for several enzymes involved in carbohydrate metabolism, including transketolase, pyruvate dehydrogenase, and α-ketoglutarate dehydrogenase. It is essential for the decarboxylation of α-keto acids and pentose phosphate pathway activity.
1 mg orally, intramuscularly, subcutaneously, or intravenously once daily for folic acid deficiency; for pregnant and lactating women: 0.4-0.8 mg orally once daily.
50-100 mg intravenously or intramuscularly once daily for deficiency; 100 mg intravenously for Wernicke encephalopathy (with 50-100 mg maintenance).
None Documented
None Documented
Terminal elimination half-life of folic acid is approximately 0.7 hours; for the active metabolite 5-methyltetrahydrofolate, half-life is 3–4 hours in plasma (tissue stores have a much longer turnover).
Terminal half-life: 9-18 days for whole body stores; plasma half-life: 1.5-2 hours for free thiamine.
Primarily excreted unchanged in urine (hepatic metabolism minimal); after oral doses, fecal excretion occurs via unabsorbed drug and biliary secretion of folate metabolites accounts for a minor route.
Renal: 40-50% as unchanged drug; metabolites: thiamine pyrophosphate, thiamine monophosphate. Fecal: minimal (<5%).
Category C
Category C
Vitamin
Vitamin